Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Controlled Study to Evaluate the Safety and Tolerability of Intradermal Administered Purified Exosome Product (PEP) in Healthy Adults

NCT06429033 is registered in ClinicalTrials.gov with Clinical Testing of Beverly Hills as lead sponsor.

NCT NCT06429033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06429033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Controlled Study to Evaluate the Safety and Tolerability of Intradermal Administered Purified Exosome Product (PEP) in Healthy Adults
Lead sponsor
Clinical Testing of Beverly Hills
Phase
Phase 1
Overall status
Completed
Start date
April 14, 2025
Completion date
December 18, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety